Tag: Medical Guidlines

Familial Hypertriglyceridemia

On July 28, 2026

When Fat in the Blood Runs in the Family

Most people know they should keep an eye on their cholesterol. But triglycerides — another type of fat circulating in the blood — often fly under the radar. For some families, though, high triglycerides aren’t just a lifestyle problem. They’re baked into the DNA. Familial hypertriglyceridemia (FHTG) is a hereditary condition in which the liver chronically overproduces fat-carrying particles, sending triglyceride levels well above what diet alone can fully explain. It’s more common than most people realize and is frequently under diagnosed. If left unaddressed it can trigger serious complications including pancreatitis and heart disease.

One of my earliest disappointments as a young physician was a patient with familial hypertriglyceridemia. He was in his late 20s and his triglycerides were running in the critical level. We tried multiple interventions and he was referred to multiple specialists. Unfortunately, he wasn’t able to make the lifestyle changes he needed to make and progressively got worse and worse before passing away in his mid-30s. Fortunately, we have better treatments now, but this still is potentially a dangerous disease.

This article walks through FHTG, what it is, what causes it, how it presents, how it’s diagnosed, and what modern medicine can actually do about it.

What Is Familial Hypertriglyceridemia?

Triglycerides are the most common form of fat in the body. After you eat, calories that your body doesn’t immediately need are converted into triglycerides and stored in fat cells. Between meals, hormones release these fats for energy. When this system gets stuck in the “on” position — or when the body doesn’t clear triglycerides efficiently — blood levels climb.

FHTG, technically classified as Type IV familial dyslipidemia, is a genetic disorder in which the liver overproduces very low-density lipoprotein (VLDL) particles — essentially the trucks that carry triglycerides through the bloodstream. The result is persistently elevated triglyceride levels, typically in the moderate-to-severe range, sometimes severe enough to become medically dangerous.

Normal fasting triglycerides are generally below 150 mg/dL. Borderline high falls between 150 and 199. In FHTG, levels often run 200–500 mg/dL or higher, and some patients can exceed 1,000 mg/dL, a threshold at which the risk of acute pancreatitis rises sharply.

Etiology: The Genetic Story Is More Complicated Than Expected

For decades, FHTG was described in textbooks as a straightforward autosomal dominant disorder — meaning one copy of a faulty gene was enough to cause the condition, and each child of an affected parent had a 50% chance of inheriting it. That picture has been substantially revised by modern genetics.

It turns out that FHTG is primarily polygenic — driven not by a single dramatic mutation but by the cumulative effect of many small genetic variants. Studies have now identified more than 300 independent genetic locations associated with plasma triglyceride levels. No single gene tells the whole story. Instead, a person inherits a kind of genetic “load” that creates susceptibility — and whether that susceptibility becomes clinically apparent often depends on environmental triggers.

The genes involved all play a role in how the body metabolizes fat-carrying particles. Heterozygous (single-copy) variants in these genes are common in most FHTG patients. The much rarer and more severe familial chylomicronemia syndrome (FCS) both copies are defective producing extreme triglyceride elevations and a very different clinical picture.

Environmental factors that worsen FHTG include obesity, poorly controlled diabetes, alcohol use, a diet heavy in refined carbohydrates and sugars, estrogen-containing medications, and certain drugs such as corticosteroids and beta-blockers. In many patients, the genetic predisposition only becomes clinically obvious when one or more of these environmental triggers is present — which explains why the condition often goes undetected until adulthood.

Symptoms: The Quiet Condition

One of FHTG’s most deceptive features is that it is often silent. Many people carry the condition for years without a single symptom, discovering it only through routine blood work or a family history investigation. This is why widespread lipid screening is so important — FHTG doesn’t announce itself with chest pain or obvious physical signs, at least not initially.

When symptoms first appear, they are often subtle and tend to reflect either the degree of triglyceride elevation or the presence of associated conditions. In cases of moderate elevation, patients might experience vague fatigue, weight gain, or features of metabolic syndrome — high blood pressure, elevated blood sugar, increased waist circumference.

At higher triglyceride levels, more distinctive signs can emerge. Xanthomas, yellowish, waxy deposits of fat under the skin, may appear, particularly around the eyelids (xanthelasmas) or over the elbows, knees, or tendons. The liver may enlarge (hepatomegaly), reflecting fat accumulation. An eye exam may show lipemia retinalis — a milky or salmon-pink discoloration of the retinal blood vessels — visible with an ophthalmoscope when triglycerides are extremely high.

The most dangerous symptom is severe abdominal pain signaling acute pancreatitis. When triglycerides exceed 1,000 mg/dL, the pancreas can become inflamed as it is overwhelmed by fat-rich particles. This is a medical emergency. Nausea, vomiting, and upper abdominal pain radiating to the back are warning signs that warrant immediate evaluation.

There is also an increased risk of early cardiovascular disease in FHTG patients, particularly when metabolic syndrome is present, though the relationship between triglycerides alone and heart disease risk is more nuanced than it is with LDL cholesterol.

Diagnosis: Getting the Full Picture

Diagnosis begins with a standard fasting lipid panel — a blood test that measures total cholesterol, LDL, HDL, and triglycerides. In FHTG, the hallmark findings are elevated triglycerides and VLDL, often accompanied by low HDL (the so-called “good” cholesterol). LDL levels may be normal or even low, which can sometimes falsely reassure both patients and physicians.

Because many things can raise triglycerides — including a meal eaten before the blood draw, excess alcohol, diabetes, hypothyroidism, kidney disease, and certain medications — the first step is ruling out secondary causes. A thorough personal and family history is essential. A clinician who asks about triglycerides in parents or siblings or even children is doing exactly what the guidelines recommend.

The “familial” part of the diagnosis is confirmed when multiple first-degree relatives are found to have elevated triglycerides, when the elevation persists despite controlling for secondary causes, and when the pattern fits what we’d expect from a heritable condition appearing across generations.

Genetic testing can identify specific variants in the related genes, but it is not required for a clinical diagnosis and is not routinely performed. Genetic testing may be ordered when the clinical picture is severe or ambiguous, or when distinguishing FHTG from the rarer familial chylomicronemia syndrome which has treatment implications such as the emerging targeted therapies.

Current guidelines also recommend evaluating for cardiovascular risk in patients with mild-to-moderate FHTG, and for pancreatitis risk in those with severe elevations.

Treatment: A Layered Approach

Lifestyle First

The cornerstone of FHTG management — at least for mild-to-moderate disease — is lifestyle modification, and it can be remarkably effective. Cutting refined carbohydrates and added sugars is particularly powerful. Saturated fat primarily raises LDL cholesterol, but it is carbohydrates that drive hepatic triglyceride production. Alcohol is another major player. Even moderate consumption can substantially raise triglycerides in susceptible individuals, and abstinence often produces dramatic improvements.

Weight loss, regular aerobic exercise, and tight blood sugar control in patients with diabetes or prediabetes round out the lifestyle toolkit. Estrogen-containing contraceptives or hormone replacement therapy should be reconsidered in women with FHTG, as estrogen directly stimulates hepatic VLDL production and can push levels dangerously high.

Pharmacologic Options

When lifestyle changes aren’t enough, several drug classes are available. Fibrates (such as fenofibrate and gemfibrozil) are the most established triglyceride-lowering medications and can reduce levels by 30–50%. They work primarily by activating receptors that enhance triglyceride clearance.

Omega-3 fatty acids at prescription doses (2–4 grams per day) provide another option. High dose eicosapentaenoic acid (EPA), specifically the formulation icosapent ethyl (Vascepa), has demonstrated cardiovascular benefit in a major clinical trial in high-risk patients with elevated triglycerides who are already on statin therapy.

Niacin (nicotinic acid) was once widely used but has fallen out of favor after clinical trials failed to show cardiovascular benefit on top of statin therapy, despite its triglyceride-lowering ability. It is also poorly tolerated due to its side effect profile and patients frequently are noncompliant.

Statins are prescribed primarily to manage cardiovascular risk and LDL cholesterol rather than to lower triglycerides directly, though they have a modest effect on the latter.

Emerging Therapies

Perhaps the most exciting development in recent years is the arrival of RNA-based medications targeting apolipoprotein C-III (APOC3) — a protein that inhibits the clearance of triglyceride-rich particles. By silencing the gene that produces APOC3, these drugs can achieve dramatic reductions in triglyceride levels even in patients who don’t respond to conventional therapies.

Olezarsen received FDA approval in 2024 for patients with familial chylomicronemia syndrome. Its application in FHTG more broadly is an active area of clinical investigation. Similarly, drugs targeting angiopoietin-like proteins are under study, offering the prospect of precision medicine approaches to a condition that has long resisted fully effective treatment.

Prognosis: Manageable, But Not to Be Ignored

The prognosis for FHTG is generally favorable when the condition is identified and managed appropriately. Unlike some other inherited lipid disorders, FHTG is not automatically associated with dramatically elevated cardiovascular risk — particularly when LDL and HDL levels are otherwise reasonable. This distinguishes it from conditions like familial hypercholesterolemia, where premature heart disease is nearly inevitable without treatment.

That said, FHTG patients frequently carry additional cardiovascular risk factors as part of the metabolic syndrome package that must be addressed in its own right. The American Heart Association has noted that this clustering of risk factors likely elevates cardiovascular risk in FHTG patients beyond what triglycerides alone would predict.

The more immediate and measurable danger in FHTG is pancreatitis. When triglycerides are severely elevated, the risk of a potentially life-threatening inflammatory episode of the pancreas is real. Repeated bouts of pancreatitis can cause chronic damage, that impairs digestive function and increases the risk of pancreatic cancer. Preventing severe hypertriglyceridemia through consistent management — lifestyle, medication, or both — is not optional for high-risk patients.

With appropriate care, most patients with FHTG can expect to live a normal lifespan. The key predictors of outcome are compliance with dietary and lifestyle changes, appropriate use of medication when indicated, regular lipid monitoring, and attention to comorbidities like diabetes and hypertension. Family members of affected individuals also should be screened.

Bottom Line

Familial hypertriglyceridemia is one of those conditions that rewards attention and penalizes neglect. It runs quietly in families, often masked by other lifestyle factors until a crisis — a pancreatitis episode, an unexpected cardiovascular event — brings it to light. Modern genetics has revealed it to be more complex than once thought, driven by a mosaic of variants rather than a single defective gene. Treatment has evolved accordingly: from basic dietary counseling to sophisticated RNA-based drugs that target the fat metabolism pathway at the molecular level.

If you have a family history of high triglycerides, early heart disease, or pancreatitis of unclear cause, it’s worth having a conversation with your doctor about a fasting lipid panel and a careful family history review. Knowing is the first step to managing.

Medical Disclaimer

The information provided in this article is intended for general educational and informational purposes only and does not constitute medical advice. It should not be used as a substitute for professional medical advice, diagnosis, or treatment.

Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking it because of something you have read here.

If you are experiencing a medical emergency, call 911 or your local emergency number immediately.

The author of this article is a licensed physician, but the views expressed here are solely those of the author and do not represent the official position of any hospital, health system, or medical organization with which the author may be affiliated.

Image generated by author using ChatGPT.

Sources

• MedlinePlus – Familial Hypertriglyceridemia

• NCBI StatPearls – Familial Hypertriglyceridemia (2024)

• Wikipedia – Familial Hypertriglyceridemia

• PMC – Genetics of Hypertriglyceridemia (Dron & Hegele, 2020)

• PMC – Understanding Hypertriglyceridemia: Integrating Genetic Insights (2024)

• PMC – Diagnosis and Treatment of Hypertriglyceridemia

• PMC – Severe Hypertriglyceridemia and Chylomicronemia Syndrome

• PMC – Pancreatic and Cardiometabolic Complications of Severe Hypertriglyceridemia (2024)

• Springer – The Genetic Basis of Hypertriglyceridemia

• Medscape – Hypertriglyceridemia: Background, Etiology, Pathophysiology

• PMC – Olezarsen for Familial Chylomicronemia Syndrome (2024-2025)

• Endocrine Society – Evaluation and Treatment of Hypertriglyceridemia (Clinical Practice Guideline)

• Cleveland Clinic – Hypertriglyceridemia: Causes, Risk Factors & Treatment

C-Reactive Protein: The Body’s Inflammation Alarm

By John Turley

On July 3, 2026

In Medicine

Structure, Function, Testing, and Clinical Implications

If you’ve ever had blood drawn during a bout of illness or a workup for heart disease risk, there’s a decent chance your doctor ordered a C-reactive protein test, usually shortened to CRP. It’s one of the most widely ordered lab tests in the world. CRP is one of the body’s most sensitive early-warning systems for inflammation. Understanding where it comes from, what it does, and how doctors use it reveals a lot about how the immune system operates and why chronic low-grade inflammation has become such a central concern in modern medicine. Warning: doctor talk will follow.

A Protein With a Peculiar Origin Story

CRP was discovered almost by accident in 1930 by William Tillett and Thomas Francis, working in Oswald Avery’s laboratory at Rockefeller University. They were studying patients with acute pneumococcal pneumonia caused by the bacteria Streptococcus pneumoniae and noticed that blood from acutely ill patients caused a specific bacterial substance to clump together. That substance was the “C polysaccharide” in the bacterial cell wall, which gave the protein its name.

For decades CRP was used as a crude yes-or-no indicator of serious infection. It wasn’t until the late 20th century that more sensitive lab techniques revealed its value for detecting the subtle, chronic inflammation now linked to cardiovascular disease and opening a major new chapter in preventive medicine. I had been in practice for several years before I even became aware of CRP.

Shape Matters: The Five-Sided Structure of CRP

CRP belongs to a protein family called the pentraxins, named from the Greek word for “five” because of the protein’s pentagonal shape. Under an electron microscope, CRP looks like five identical subunits arranged in a ring, roughly like five coins fanned into a disc. For history buffs, it resembles the five-star rank worn by General Eisenhower.

Each subunit carries a binding site made of two calcium ions nestled next to a small hydrophobic pocket. This is where CRP does its recognition work: the calcium-dependent sites allow it to grab onto phosphocholine (PC), a molecule found in the membranes of damaged and dying cells, as well as in the outer coatings of many bacteria and fungi. Phosphocholine is so widespread in biology that this single binding chemistry lets CRP respond to an enormous range of threats including microbial invaders and the body’s own dead cells.

CRP doesn’t always exist in this five-subunit ring form. The pentameric version (pCRP) circulates in healthy blood. But at sites of active tissue damage, such as inside an inflamed artery wall, it can break apart into individual monomers (mCRP). These two forms turn out to have strikingly different effects on the immune system.

What CRP Does

It’s tempting to think of CRP as a passive number on a lab report, but it’s actually an active participant in the immune response. It plays at least four major roles.

First, CRP is a pattern recognition molecule. Unlike the antibodies generated by your adaptive immune system which take days or weeks to respond to a specific threat, CRP responds immediately to general molecular patterns shared by pathogens and damaged cells. This makes it a first-responder tool within the innate immune system, the body’s rapid defense network.

Second, once CRP binds to a pathogen or dying cell, it acts as an opsonin, essentially a molecular flag that says “eat this.” Immune cells called phagocytes (macrophages and neutrophils) recognize CRP-coated targets and engulf them, accelerating the clearance of both bacteria and cellular debris.

Third, CRP can activate the complement system, a cascade of proteins that further tags pathogens for destruction. Crucially, CRP appears to stop short of triggering the most destructive steps of that cascade. The net effect is a measured, targeted immune response rather than an all-out inflammatory assault.

Fourth, and this is where things get interesting, the pentameric and monomeric forms of CRP have opposing effects. The pentameric form in circulation is primarily anti-inflammatory, quietly clearing dead cells without triggering unnecessary immune activation. But the monomeric form that appears at sites of tissue damage can amplify inflammation: activating platelets, recruiting immune cells to vessel walls, and stimulating the release of the inflammatory signaling molecule. CRP is neither simply good nor simply bad — it’s context-dependent, functioning as a careful janitor in healthy tissue but potentially fanning the flames in already-inflamed environments.

Fast, Sensitive, and Liver-Made

CRP is produced primarily by liver cells (hepatocytes) in response to immune signals. When immune cells detect infection or tissue damage, they release cytokines, which travel to the liver and switch on CRP production.

One of CRP’s great clinical virtues is speed. Levels can begin rising within four to six hours of an inflammatory event and typically peak within 24 to 48 hours. When the inflammation resolves, CRP falls just as quickly, its half-life in circulation is only about 19 hours. This fast-on, fast-off behavior makes CRP an excellent real-time readout of what the immune system is doing right now, not weeks ago. Because of this early availability, it is referred to as an acute phase reactant.

Under normal, non-inflammatory conditions, CRP in the blood typically measures below 1 milligram per liter (mg/L). During serious bacterial infection or major tissue injury, levels can spike above 400 mg/L — a several-hundred-fold increase. CRP also has a practical advantage for testing: it doesn’t fluctuate throughout the day, and fasting is not required before a blood draw.

The Many Uses of CRP in Clinical Medicine

The oldest application of CRP testing is detecting and monitoring bacterial infection. Very high values — generally above 100 mg/L — strongly suggest bacterial rather than viral infection, since viruses tend to provoke a much more modest CRP rise. In sepsis (the life-threatening systemic response to infection), CRP is one of several markers used to assess severity and track the response to treatment.

CRP is also routinely used to monitor autoimmune diseases. In rheumatoid arthritis, CRP is included in standard disease activity scoring tools. Tracking CRP over time helps clinicians judge whether treatments like disease-modifying drugs are working. One notable exception: in systemic lupus erythematosus (SLE), CRP often stays surprisingly low even during active flares.

Perhaps the most debated expansion of CRP testing in recent decades is its role in cardiovascular risk assessment. That story begins with the recognition that atherosclerosis, the plaque buildup inside artery walls, is fundamentally an inflammatory process, not just a plumbing problem caused by too much cholesterol. As that insight took hold in the 1990s, researchers began asking whether CRP could predict heart attack risk the way cholesterol does.

The answer was yes, but only with a more sensitive test. Standard CRP assays can’t detect levels below about 10 mg/L, which is fine for infections but misses the chronic low-level inflammation relevant to cardiovascular risk. A newer high-sensitivity CRP test (hs-CRP) can measure levels as low as 0.01 mg/L. Using hs-CRP, researchers found that even modest CRP elevations, within the range once considered entirely normal, carry meaningful cardiovascular risk.

The American Heart Association and the CDC use these hs-CRP thresholds for cardiovascular risk: below 1 mg/L is low risk; 1 to 3 mg/L is intermediate risk; above 3 mg/L is higher risk. A large UK Biobank analysis of nearly 450,000 people found that individuals with hs-CRP above 3 mg/L had a 34% higher risk of major cardiovascular events and a 61% higher risk of cardiovascular death compared to those below 1 mg/L.

The landmark JUPITER trial demonstrated that patients with low LDL cholesterol, but elevated hs-CRP (above 2 mg/L) still benefited substantially from statin therapy — in terms of reduced heart attacks and strokes. This reframed how cardiologists think about inflammation as a cardiovascular target independent of cholesterol levels.

Beyond infection, autoimmune disorders, and heart disease, elevated CRP has been linked to type 2 diabetes, metabolic syndrome, chronic kidney disease, COPD, depression, and neurodegenerative diseases, all conditions where chronic low-grade inflammation is increasingly recognized as a contributing factor rather than just a side effect.

Measuring CRP: The Standard Test vs. the High-Sensitivity Test

CRP testing is straightforward, just a standard blood draw, no fasting required. Modern automated lab analyzers make it fast and inexpensive, which explains why it shows up so often in clinical workups.

The standard CRP test is the workhorse for detecting acute infection and monitoring inflammatory flares in hospitalized patients. The hs-CRP test uses more sensitive techniques and is the test used for cardiovascular risk assessment.

Because hs-CRP can fluctuate modestly from day to day, cardiovascular guidelines recommend averaging two measurements taken about two weeks apart. Acute illness, recent injury, or even a hard workout can temporarily elevate hs-CRP and produce a misleading result.

Several factors can push CRP higher independently of the disease in question: obesity, smoking, high blood pressure, metabolic syndrome, low HDL cholesterol, and chronic low-grade infections such as gum disease. Age also gradually raises baseline CRP. On the other side, moderate physical activity, weight loss, and statins are all associated with lower CRP — which partly explains the broader cardiovascular benefits of statin therapy beyond cholesterol reduction.

What CRP Can’t Tell You

For all its usefulness, CRP is a nonspecific marker. A reading of 50 mg/L is consistent with a kidney infection, an autoimmune flare, a recent heart attack, or an abdominal cancer. CRP tells you that inflammation or tissue damage is happening somewhere; it doesn’t tell you where or why. Clinical context including symptoms, medical history, and other lab results, is essential for interpretation.

There’s also a genuine unresolved debate about whether CRP elevation actually causes cardiovascular disease or is simply a marker of underlying inflammatory risk. Animal studies in CRP-deficient or CRP-enhanced models have produced inconsistent results. Mendelian randomization studies in humans, a statistical technique that uses genetic variants to approximate a randomized experiment, have generally not supported CRP as a causal driver of heart disease, suggesting it may be more of a reaction than a root cause.

Finally, hs-CRP testing, despite strong evidence, remains underused in primary care, particularly in primary prevention. The 2024 European Society of Cardiology guidelines for chronic coronary syndromes did recommend assessing hs-CRP in patients with suspected coronary artery disease, which reflects accumulating evidence for its utility, but broader implementation lags behind the science. I have to admit, when I was still in active practice, I was unaware of the role of hs-CRP in primary prevention. At the time, it was generally thought to be of use in secondary prevention—actions taken after an initial event. Be sure and ask your doctor about it.

CRP is, in the end, a remarkably versatile tool — a protein that has been doing immune surveillance since long before medicine had a name for it, and one that continues to find new clinical relevance with each decade of research.

Medical Disclaimer

If you are experiencing a medical emergency, call 911 or your local emergency number immediately.

Image generated by the author using ChatGPT

Sources

The following peer-reviewed and clinical references support this article:

Zhou et al. (2024). C-reactive protein: structure, function, regulation, and role in clinical diseases. Frontiers in Immunology. — https://pmc.ncbi.nlm.nih.gov/articles/PMC11211361/

Agrawal & Wu (2024). Editorial: Biology of C-reactive protein. Frontiers in Immunology. — https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1445001/full

Volanakis (2001). Human C-reactive protein: expression, structure, and function. Molecular Immunology. PubMed. — https://pubmed.ncbi.nlm.nih.gov/11532280/

Thompson et al. (2004). C-reactive protein. Journal of Biological Chemistry. — https://www.jbc.org/article/S0021-9258(19)32228-8/fulltext

Salazar et al. (2014). C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation. International Scholarly Research Notices. PMC. — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897210/

StatPearls: C-Reactive Protein: Clinical Relevance and Interpretation. PubMed. — https://pubmed.ncbi.nlm.nih.gov/28722873/

Medscape: High-Sensitivity C-Reactive Protein: Reference Range, Interpretation. — https://emedicine.medscape.com/article/2094831-overview

Ridker PM (2003). High-sensitivity C-reactive protein: clinical importance. PubMed. — https://pubmed.ncbi.nlm.nih.gov/15258556/

Kraaijenhof et al. (2025). LDL cholesterol, CRP, and lipoprotein(a) universal screening. European Heart Journal. ACC summary. — https://www.acc.org/latest-in-cardiology/articles/2025/12/01/01/prioritizing-health-hscrp

Johns Hopkins Medicine: Assessing Cardiovascular Risk with C-Reactive Protein. — https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/assessing-cardiovascular-risk-with-c-reactive-protein

Labcorp: C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment). — https://www.labcorp.com/tests/120766/c-reactive-protein-crp-high-sensitivity-cardiac-risk-assessment

Larsen et al. (2024). C-reactive protein and cardiovascular risk in the general population. European Heart Journal. — https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf937/8377304

Shetty & Kawaguchi (2024). Role of CRP in disease progression, diagnosis and management. PMC. — https://pmc.ncbi.nlm.nih.gov/articles/PMC11569793/

McDonnell et al. (2024). C-reactive protein complement-ary structures in RA. Elsevier/Immunology Letters. — https://www.binasss.sa.cr/ago24/21.pdf

CRP kinetics as predictor in immune checkpoint inhibitor therapy. BJC Reports / Nature. — https://www.nature.com/articles/s44276-023-00005-x

Borges et al. (2024). Battle of the Biomarkers of Systemic Inflammation (CRP vs cfDNA). PMC. — https://pmc.ncbi.nlm.nih.gov/articles/PMC12024891/

Assay Genie: C-reactive protein — structure and function overview. — https://www.assaygenie.com/blog/c-reactive-protein

WebMD: C-Reactive Protein Test: High vs. Low Levels. — https://www.webmd.com/a-to-z-guides/c-reactive-protein-test

Mayo Clinic: C-reactive protein test. —https://www.mayoclinic.org/tests-procedures/c-reactive-protein-test/about/pac-20385228

Hepatitis B Vaccine: Three Shots and You’re Done for Life?

By John Turley

On January 28, 2026

In Medicine

If you’re trying to figure out whether you need a hepatitis B vaccine or wondering if the one you got years ago is still protecting you, you’re not alone. The hepatitis B vaccine is one of those medical interventions that raises straightforward questions: How many shots do you need? And does it really last forever? I thought I should follow up last week’s general discussion of hepatitis with some specifics on this vaccine.

The Shot Schedule

The traditional hepatitis B vaccine series requires three shots spaced over six months. You get the first dose, then return for a second shot one to two months later and finally complete the series with a third dose at the six-month mark. There is also a combination hepatitis A and B vaccine that follows the same schedule. This schedule has been the standard for decades and works well for both children and adults.

But here’s something newer: In 2017, the FDA approved a two-dose hepatitis B vaccine called Heplisav-B for adults 18 and older. With this option, you only need two shots spaced one month apart. For parents of young children, there is Pediarix, a combination vaccine that bundles hepatitis B protection with vaccines for other diseases, streamlining the infant immunization schedule.

Does It Really Last a Lifetime?

This is where the science gets interesting. The short answer is yes, for most people the protection appears to be lifelong. But the mechanism behind this is more nuanced than you might expect.

After you complete the vaccine series, your body produces antibodies against hepatitis B. Over time—sometimes after just a few years—the level of these antibodies in your blood can decline to the point where they’re barely detectable or even undetectable. On the surface, that sounds concerning. But here’s the key: your immune system has memory.

Even when antibody levels drop, your body retains specialized immune cells that “remember” hepatitis B. If you encounter the virus years or decades later, these memory cells spring into action, rapidly producing new antibodies to fight off the infection before it can establish itself. Researchers have followed vaccinated individuals for more than 30 years and found that this immune memory remains protective even when blood tests show low antibody levels.

Who Might Need a Booster?

For most people with healthy immune systems, the CDC doesn’t recommend booster shots. Once you’ve completed the series and your body has responded appropriately, you’re considered protected. However, there are exceptions. People with compromised immune systems—such as those undergoing dialysis, living with HIV, or taking immunosuppressive medications—may need periodic booster doses. These individuals should work with their healthcare providers to monitor their antibody levels and determine if additional shots are necessary.

The Bottom Line

The hepatitis B vaccine is a three-shot series (or two shots with the newer formulation) that provides protection that researchers believe lasts a lifetime for most people. While your antibody levels might decline over the years, your immune system’s memory keeps you safe. It’s one of those rare cases where you can check something off your health to-do list and genuinely move on.

Sources:

CDC Hepatitis B Vaccination: https://www.cdc.gov/hepatitis/hbv/vaccineadults.htm
FDA Vaccines Information: https://www.fda.gov/vaccines-blood-biologics/vaccines/heplisav-b

Understanding Hepatitis: A Guide to Types A, B, and C

By John Turley

On January 21, 2026

In Medicine

If you’ve heard of hepatitis, you probably know it has something to do with the liver. But there’s a whole family of hepatitis viruses, each with its own personality when it comes to how it spreads, what it does to your body, and how we can prevent or treat it. Let’s walk through the three most common types—hepatitis A, B, and C—and then dive into a controversy that’s making headlines right now: the hepatitis B vaccine.

What Is Hepatitis, Anyway?

At its core, hepatitis just means inflammation of the liver. Your liver is a workhorse organ that filters toxins, produces essential proteins like albumin, processes amino acids, and stores energy. When a hepatitis virus attacks it, the inflammation can range from a minor inconvenience to a life-threatening condition. The three main culprits—hepatitis A, B, and C viruses—are completely different organisms that just happen to target the same organ.

Hepatitis A: The Food and Water Troublemaker

Hepatitis A is often called “traveler’s hepatitis” because it spreads through food and water that are contaminated with fecal matter. Think of it as the virus you might pick up from eating unwashed produce, drinking contaminated water, or consuming raw shellfish from polluted waters. Other risk factors include unprotected sex and IV drug use. According to the CDC, there were an estimated 3,300 acute infections in 2023 in the United States.

The good news about hepatitis A is that it typically heals itself within 2 months. When symptoms appear—which take about 15 to 50 days after infection—they can include jaundice (that yellowing of the skin and eyes), fever, fatigue, nausea, and dark urine. Many young children don’t show any symptoms at all. The virus doesn’t become chronic, and once you’ve had it, your body produces antibodies that protect you for life.

Prevention is straightforward: there’s a safe and effective vaccine, and basic hygiene goes a long way. Wash your hands thoroughly, especially after using the bathroom and before preparing food. When traveling to areas with questionable water quality, stick to bottled or boiled water and avoid washing raw food in local water.

Treatment is mostly supportive—rest, fluids, and time. Your liver does the healing work itself.

Hepatitis B: The Blood and Body Fluid Virus

Hepatitis B is where things get more serious. This virus spreads through blood and other body fluids, which means it can be transmitted through sexual contact, sharing needles, or from mother to baby during childbirth. Healthcare workers are especially at risk from needle sticks and sharps injuries. It’s a highly infectious and tough virus that can live on surfaces for up to a week. Even tiny amounts of dried blood on seemingly innocent things like razors, nail clippers, or toothbrushes can potentially spread the infection.

According to the CDC, there were an estimated 14,400 acute infections in 2023, Approximately 640,000 adults were living with chronic hepatitis B during the 2017-2020 period and that’s what makes it particularly concerning: while the hepatitis B virus often causes short-term illness, it can become chronic.

The incubation period is long—typically 90 days with a range of 60 to 150 days. When symptoms do appear, they mirror hepatitis A: jaundice, fatigue, abdominal pain, nausea, and dark urine. But here’s the frightening part: most young children and many adults show no symptoms at all, meaning they can spread the virus without knowing they’re infected.

The chronic infection risk varies dramatically by age. If you’re infected as a newborn, you have a 90% chance of developing chronic hepatitis B. For adults, the risk drops to under 5%. Those with chronic infection face serious long-term consequences—15% to 25% of people with chronic infection develop serious liver disease, including cirrhosis, liver failure, or liver cancer.

Treatment for acute hepatitis B is supportive, but several antiviral medications are available for people with chronic infection. These don’t completely eradicate the disease but produce a “functional cure” that significantly slows liver damage and reduces complications.

Prevention is critical. There’s a highly effective vaccine—we’ll talk more about the controversy surrounding it in a moment. Avoiding exposure to infected blood and body fluids is essential. This means safe sex practices, never sharing needles or personal care items that might have blood on them, and ensuring proper sterilization of medical and tattooing equipment.

Hepatitis C: The Silent Epidemic

Hepatitis C is transmitted primarily through blood-to-blood contact. The most common route is sharing needles among people who inject drugs, though it can also spread through contaminated medical equipment, and rarely through sexual contact. Mother-to-child transmission during childbirth is possible but uncommon. Screening of blood products has made transfusion related infections rare. About 10% of cases have no identified source.

What makes hepatitis C insidious is its stealthy nature. Many people with hepatitis C don’t have symptoms, and acute hepatitis with jaundice is rare, occurring in only about 10% of infections. The symptoms that do appear—fatigue, mild flu-like feelings—are easily dismissed. Meanwhile, the majority of people (60-70%) develop chronic infection. I recommend a screening blood test at least once for all adults over age 55, as they are the group most likely to have hepatitis C without an identifiable source.

The incubation period ranges widely, from 2 weeks to 6 months, typically 6 to 9 weeks. Without treatment, chronic hepatitis C can lead to cirrhosis and liver cancer over decades. Before modern treatments, it was a leading cause of liver transplants.

Treatment for hepatitis C has undergone a revolution. The old approach—interferon injections combined with ribavirin—had terrible side effects and worked in only about half of patients. Today, we have direct-acting antivirals (DAAs), which can cure more than 95% of cases with just 8-12 weeks of well-tolerated oral medication. These drugs target specific proteins the virus needs to replicate, essentially starving it out of existence. The treatment is so effective that hepatitis C is now considered a curable disease.

Prevention focuses on avoiding blood-to-blood contact. Never share needles, syringes, or any drug equipment. If you’re getting a tattoo or piercing, ensure the facility follows proper sterilization procedures. Healthcare workers should follow standard precautions with blood and body fluids. Unfortunately, there’s no vaccine for hepatitis C yet, though researchers continue working on one.

The Hepatitis B Vaccine Controversy: What’s Really Happening

Now let’s address the elephant in the room—the recent controversy over the hepatitis B vaccine for newborns. This topic exploded in the news in December 2025, and it’s worth understanding what’s currently going on versus what the science says.

The Recent Development

On December 5, 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8-3 to recommend hepatitis B vaccination at birth only for infants born to mothers who test positive for the virus or whose status is unknown. This reverses decades of policy that recommended universal hepatitis B vaccination for all newborns within 24 hours of birth.

The Arguments For Changing the Policy

Some ACIP members raised concerns about vaccine safety and parental hesitancy. Committee member Retsef Levi heralded the move as “a fundamental change in the approach to this vaccine,” which would encourage parents to “carefully think about whether they want to take the risk of giving another vaccine to their child”. The controversy includes historical concerns about possible links between the hepatitis B vaccine and conditions like multiple sclerosis, autism, and other autoimmune disorders.

What Science Actually Shows

The evidence on vaccine safety is quite robust. Concerns about multiple sclerosis emerged in France in the 1990s. Since then, a large body of scientific evidence shows that hepatitis B vaccination does not cause or worsen MS. The World Health Organization’s Global Advisory Committee on Vaccine Safety has concluded there is no association between the hepatitis B vaccine and MS. It is one of the safest vaccines studied.

As for other safety concerns, CDC reviewed VAERS reports from 2005-2015 and found no new or unexpected safety concerns. The most common side effects are minor: soreness at the injection site, headache, and fatigue lasting 1-2 days.

Why the Universal Birth Dose Matters

The scientific and medical communities have strongly opposed this policy change. The American Academy of Pediatrics states that from 2011-2019, rates of reported acute hepatitis B remained low among children and adolescents, likely explained in part by the implementation of childhood hepatitis B vaccine recommendations published in 1991.

Here’s why newborns are so vulnerable: infected infants have a 90% chance of developing chronic hepatitis B, and a quarter of those will die prematurely from liver disease when they become adults.

The “just target high-risk babies” approach has a major flaw: the CDC estimates about 640,000 adults have chronic hepatitis B, but about half don’t know they’re infected. Before universal vaccination, about half of infected children under 10 got it from their mothers—the rest contracted it through other exposures not identified by maternal screening.

The Global Context

Claims that the U.S. is an outlier don’t hold up. As of September 2025, 116 of 194 WHO member states recommend universal hepatitis B birth dose vaccination. European countries that do not recommend a universal birth dose have a much lower hepatitis B incidence rate and more robust antenatal maternal screening. The majority still recommend vaccination at two to three months.

The Bottom Line

All three types of hepatitis pose serious health risks, but we have powerful tools to prevent and treat them. Hepatitis A and B have safe, effective vaccines that have dramatically reduced disease rates. Hepatitis C, while lacking a vaccine, is now curable with modern antiviral medications.

The hepatitis B vaccine controversy highlights a broader tension in public health: balancing individual autonomy with community protection. The scientific evidence strongly supports the vaccine’s safety and the effectiveness of universal newborn vaccination in preventing a disease that can be fatal. Multiple studies, decades of safety data, and recommendations from medical organizations worldwide back this up.

For parents making decisions about their newborns, the facts are these: hepatitis B is a serious disease with a high risk of becoming chronic in infants, the vaccine is highly effective at preventing infection, and extensive safety monitoring has found it to be safe with only minor, temporary side effects. As hepatitis research continues, we’re seeing remarkable progress—from the near-eradication of hepatitis A in vaccinated populations to the transformation of hepatitis C from a chronic, often fatal disease to a curable one. These advances remind us how far we’ve come in understanding and combating these liver viruses.

Sources

Centers for Disease Control and Prevention (https://www.cdc.gov)
World Health Organization (https://www.who.int)
Cleveland Clinic (https://my.clevelandclinic.org)
National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov)
American Academy of Pediatrics (https://www.aap.org)
PBS NewsHour (https://www.pbs.org)
FactCheck.org (https://www.factcheck.org)
Government of Quebec (https://www.quebec.ca/en/health/health-issues/stbbis/hepatitis-a-b-and-c)

Understanding Parkinson’s Disease: From Diagnosis to Daily Living

By John Turley

On December 13, 2025

In Medicine, Uncategorized

When most people think of Parkinson’s disease, they picture the characteristic tremor—that involuntary shaking that has become almost synonymous with the condition. But the reality is far more complex than just one visible symptom. Let’s dig into what’s actually happening in the brain, how doctors figure out what’s going on, and what living with this condition really looks like.

What Causes Parkinson’s Disease?

Here’s where things get frustrating for researchers: despite decades of study, scientists still don’t know exactly what causes the nerve cells in the brain to die. I’m going to apologize in advance because I’m going to be using a lot of “doctor talk”—no way around it.

What we do know is that nerve cells (neurons) in the substantia nigra portion of the basal ganglia—an area of the brain controlling movement—become impaired or die, and these neurons normally produce dopamine, an important brain chemical. When these cells stop working properly, dopamine levels drop, and that’s when movement problems begin showing up.

But dopamine isn’t the whole story. People with Parkinson’s also lose nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which helps explain why the disease affects so much more than just movement—things like blood pressure, digestion, and energy levels all take a hit.

Most Parkinson’s cases are idiopathic, meaning the cause is unknown, though contributing factors have been identified. Current thinking suggests a complicated mix of genetic and environmental factors. About 5% to 10% of cases begin before age 50, and these early-onset forms are often, though not always, inherited.

Some risk factors have emerged from research: age is the most significant, with about 1% of those over 65 and around 4.3% of those over 85 affected. Traumatic brain injury significantly increases risk, especially if recent, and repeated head injuries from contact sports can cause what’s called post-traumatic parkinsonism. Muhammad Ali is a classic example of this.

Exposure to pesticides and industrial chemicals has also been identified as a risk factor. Interestingly, large epidemiologic studies consistently show that people who smoke have a lower risk of being diagnosed with Parkinson’s disease than never‑smokers, although smoking is still strongly discouraged because of its many harmful health risks. Large cohort studies in the U.S. and Europe generally find no direct association between alcohol consumption and Parkinson’s disease. A few observational studies show that moderate drinkers have slightly lower Parkinson’s rates. However, researchers believe this may be due to reverse causation (people in early or undiagnosed stages often reduce drinking because of GI or mood changes) and lifestyle confounders (moderate drinkers may differ in socioeconomic status, diet, or activity level). So, the “protective” effect is considered speculative, not causal.

The Symptoms: More Than Just Shaking

The hallmark movement symptoms—what doctors call “motor symptoms”—are what usually bring people to the doctor. Slowed movements, called bradykinesia, is required for a Parkinson’s diagnosis. People describe it as muscle weakness, though it’s really about control, not strength. The classic tremor, stiffness, and balance problems round out the main movement issues. Patients frequently show reduced arm swing, shuffling gait, difficulty initiating movement or turning, masked facial expression, decreased blinking, and soft or monotone speech.

But here’s what often surprises people: many individuals later diagnosed with Parkinson’s notice that prior to experiencing stiffness and tremor, they had sleep problems, constipation, loss of smell, and restless legs. These “prodromal symptoms” can show up years before the movement problems become obvious. Other early signs include mood disorders like anxiety and depression.

The cognitive side deserves attention too. Some people experience changes in cognitive function, including problems with memory, attention, and the ability to plan and accomplish tasks, though hard to pin down due to concurrence with age related memory problems, 20% at the time of diagnosis is a commonly cited number. More contested is how many develop Parkinson’s dementia, with estimates ranging from 20% all the way to 85%.

How Doctors Make the Diagnosis

Here’s something that might surprise you: there are currently no blood or laboratory tests to diagnose non-genetic cases of Parkinson’s. The standard diagnosis is clinical, meaning there’s no test that can give a conclusive result—certain physical symptoms need to be present.

Doctors typically diagnose Parkinson’s by taking a detailed medical history and performing a neurological examination. If symptoms improve after starting medication, that’s another indicator that the person has Parkinson’s.

There are some imaging tools available. The FDA approved an imaging scan called the DaTscan in 2011, which allows doctors to see detailed pictures of the brain’s dopamine system using a radioactive drug and SPECT scanner. But this scan can’t definitively diagnose Parkinson’s though it helps rule out conditions that mimic it. A hallmark of Parkinson’s is the buildup of misfolded alpha-synuclein proteins (Lewy bodies) inside neurons. Whether this is a cause, an effect, or both is still under study—this part of the science remains somewhat speculative.

Recently, researchers developed something more promising: the alpha-synuclein seeding amplification assay can detect abnormal alpha-synuclein in spinal fluid and may detect Parkinson’s in people who haven’t been diagnosed yet. The catch? It requires a spinal tap and isn’t widely available, though scientists are working on blood and saliva tests.

The early diagnostic challenge is real. Many disorders can cause similar symptoms, and people with Parkinson’s-like symptoms from other causes are sometimes said to have parkinsonism, which includes conditions like multiple system atrophy and Lewy body dementia that require different treatments.

What to Expect: The Prognosis

Let’s address the big question: how does Parkinson’s affect life expectancy? The news here is better than you might think. The average life expectancy of a person with Parkinson’s is generally the same as for someone without the disease.

More specifically, average life expectancy has increased by about 55% since 1967, rising to more than 14.5 years from diagnosis. Modern treatments have made a huge difference. Research indicates that those with Parkinson’s and normal cognitive function appear to have a largely normal life expectancy.

That said, timing matters. Research from 2020 suggests that people who receive a diagnosis before age 70 usually experience a greater reduction in life expectancy, and males with Parkinson’s may have a greater reduction in life expectancy than females.

The disease is progressive, meaning it gets worse over time, but symptoms and progression vary from person to person, and neither you nor your doctor can predict which symptoms you’ll get, when, or how severe they’ll be. The tremor-dominant type usually has a more favorable prognosis than the hypokinetic type.

What actually causes death in advanced Parkinson’s? Advanced symptoms can cause falls, pressure ulcers, swallowing difficulties and general frailty, all of which are linked to death. Aspiration pneumonia—when you inhale food or liquid into the lungs—is the leading cause of death for people with Parkinson’s.

Managing the Disease

Currently, there’s no cure for Parkinson’s, but medications or surgery can improve many of the movement symptoms.

The gold standard medication is levodopa (often combined with carbidopa as Sinemet). Healthcare providers use levodopa cautiously and they commonly combine it with other medications to keep your body from processing it before it enters your brain. This helps avoid side effects like nausea, vomiting, and low blood pressure when standing up. The tricky part? Over time, the way your body uses levodopa changes, and it can lose effectiveness.

Beyond levodopa, doctors use MAO-B inhibitors and dopamine agonists. As the disease progresses, these medications become less effective and may cause involuntary muscle movements. When drugs stop working well, there are surgical options to treat severe motor symptoms.

The main surgical treatment today is called deep brain stimulation (DBS). It is the most important therapeutic advancement since the development of levodopa, and it’s been FDA-approved since the late 1990s A surgeon places thin metal wires called electrodes into one or both sides of the brain, in specific areas that control movement. A second procedure implants an impulse generator battery under the collarbone or in the abdomen. It is similar to a heart pacemaker and about the size of a stopwatch, this device delivers electrical stimulation to those targeted brain areas.

A new treatment that is being used is focused ultrasound. Guided by MRI, high-intensity, inaudible sound waves are emitted into the brain, and where these waves cross, they create high energy that destroys a very specific area connected to tremor. It’s considered non-invasive and the FDA has approved it for Parkinson’s tremor that doesn’t respond to medications.

Don’t underestimate lifestyle interventions either. Physical therapy can improve balance and address muscle stiffness, and regular exercise improves strength, flexibility, and balance. Eating a balanced diet helps—drinking plenty of water and eating enough fiber reduces constipation, while omega-3 fats and magnesium may boost cognition and help with anxiety.

Parkinson’s disease sits at the intersection of aging, genetics, environment, and biology. Diagnosis is clinical, progression is gradual and variable, and treatment has become increasingly sophisticated. While it remains incurable, early diagnosis, personalized medication plans, targeted therapies like DBS, and consistent exercise allow many people to maintain meaningful independence for years.

The key message from specialists? Treatment makes a major difference in keeping symptoms from having worse effects, and adjustments to medications and dosages can hugely impact how Parkinson’s affects your life.

When Your World Goes Dark: A Simple Guide to Fainting

By John Turley

On November 25, 2025

In Uncategorized

So you want to know about fainting—or as doctors call it, “syncope” (sink-oh-pee)? Let’s talk about it like we’re grabbing coffee, because this is something that happens to a lot of people and it’s worth understanding.

What’s Actually Happening When You Faint

Here’s the basics: fainting is when your brain temporarily doesn’t get enough blood flow, and it hits the “off” switch for a few seconds. Your body does this as a protective mechanism—when you’re horizontal on the ground, it’s easier for blood to reach your brain again. Not exactly elegant, but your body is doing its best.

Most of the time, you’ll get some warning signs before you go down. Your vision might get blurry or narrow like you’re looking through a tunnel. You might feel dizzy, sweaty, nauseous, or just generally weird and weak. Some people describe feeling really warm right before it happens. If you’re lucky enough to recognize these signs, you can sometimes sit or lie down before you actually lose consciousness.

When you do faint, it usually only lasts a few seconds to maybe a couple minutes. You’ll collapse, your muscles will relax, and you’ll be out. Sometimes your body might jerk a little bit—not like a full seizure, just brief movements because your brain is momentarily starved for oxygen. Then you wake up, usually within moments, you’re back to normal, though you might feel tired or a bit confused for a short while.

Why This Happens: The Age Factor

The interesting thing is that why people faint changes a lot depending on how old they are.

If you’re younger, the most common culprit is what’s called vasovagal syncope, your nervous system overreacts to something and suddenly drops your heart rate and blood pressure. This can happen when you’re stressed, in pain, standing for too long, or even just dehydrated. Ever heard someone say they “can’t stand the sight of blood” or they got woozy at a concert? That’s usually vasovagal syncope. Standing up too fast is another big one—you’ve probably experienced that head rush where everything goes spotty for a second. Sometimes specific situations trigger it: coughing really hard, swallowing, even urinating or exercising intensely can mess with your blood pressure just enough to cause problems.

There are also some rarer causes in young people, like inherited heart rhythm problems—conditions with names like long QT syndrome or Wolff-Parkinson-White syndrome. These are less common but more serious.

For older adults, the picture changes. The autonomic nervous system—your body’s autopilot for things like blood pressure—doesn’t work quite as smoothly as you age. Add in multiple medications (especially blood pressure meds and diuretics), some chronic dehydration (common as people get older) and you’ve got a recipe for more frequent dizzy spells when standing up. Some older folks develop something called carotid sinus hypersensitivity, where even turning their head or wearing a tight collar can trigger a drop in heart rate or blood pressure.

Heart-related causes become much more common with age too. Irregular heartbeats like atrial fibrillation, problems with the heart’s electrical system, or structural issues like a stiff aortic valve or weakened heart muscle can all lead to fainting. And let’s not forget medications—beta-blockers, vasodilators, and certain antidepressants— can all lower blood pressure enough to cause problems.

When Should You Worry?

Here’s where we need to get serious for a second. Most fainting episodes aren’t dangerous, but some are red flags that need immediate attention.

Get emergency help if fainting comes with chest pain, a racing or pounding heartbeat, or trouble breathing—these could mean something’s wrong with your heart. Also, if there are any neurological symptoms like sudden confusion, trouble speaking, weakness on one side of your body, or difficulty understanding people, then you need to rule out things like stroke or seizure right away.

Even without those scary symptoms, if you’re fainting repeatedly or can’t figure out why it’s happening, you should definitely see a doctor. Recurrent fainting can point to underlying issues that are worth catching early—both for safety (falling and hitting your head is no joke) and for quality of life.

How Doctors Figure It Out?

When you go to see a doctor about fainting, they’re playing detective. They’ll want to know everything: What were you doing when it happened? What did you feel beforehand? Did anyone see you faint—and if so, what did they observe? How did you feel afterward? They’ll also ask about your family history (especially sudden cardiac deaths) and what medications you’re taking.

The physical exam usually includes checking your blood pressure and heart rate while you’re lying down and then again when you stand up—this can reveal orthostatic hypotension (that fancy term for your blood pressure dropping when you stand). They’ll listen to your heart, check your neurological function, and look for any obvious problems.

Almost everyone gets an electrocardiogram (EKG)—that test where they stick electrodes on your chest to measure your heart’s electrical activity. Depending on what they find, you might get blood work to check for things like anemia, blood sugar problems, or electrolyte imbalances. An ultrasound of your heart (echocardiogram) might be ordered if they suspect structural heart disease.

If you keep fainting or if there’s concern about your heart, they might want continuous monitoring. This could be anything from wearing a Holter monitor for 24 hours to having a tiny device implanted under your skin that can record your heart rhythm for weeks or even longer. There’s also something called a tilt table test, where they literally tilt you upward on a table to see if it triggers fainting—sounds medieval but it’s useful for diagnosing vasovagal syncope.

Living With It: What You Can Do

The good news is that for most types of fainting, there’s a lot you can do to prevent it from happening again.

If you have the common vasovagal type, learning to recognize those warning signs is huge. Once you feel them coming on, you can do what’s called “counter-pressure maneuvers”—crossing your legs and tensing them, squeezing your hands together really hard, or tensing your arm muscles. These actions help keep your blood pressure up and can stop you from fainting.

Lifestyle changes make a real difference too. Stay hydrated—seriously, drink more water than you think you need. Avoid your known triggers if you can identify them. When you’ve been sitting or lying down, stand up slowly in stages rather than popping right up. Some people benefit from compression stockings (yeah, they’re not glamorous, but they work). Your doctor might even tell you to eat more salt, which is probably the only time a healthcare provider will ever tell you to do that.

For orthostatic hypotension, the management is similar—hydrate, rise slowly, maybe do some calf muscle exercises. Your doctor will also review your medications to see if anything can be adjusted or eliminated.

If your fainting is related to a heart problem, treatment gets more specific and serious. This could mean medications to control heart rhythm, procedures to fix abnormal electrical pathways in your heart, or even implanting a pacemaker or defibrillator. The treatment depends entirely on what specific problem you have.

No matter what’s causing your fainting, regular follow-up with your doctor is important. They need to see if treatments are working, adjust things if necessary, and catch any new issues early.

The Bottom Line

Fainting is super common, but it’s also something you shouldn’t try to diagnose yourself. While most episodes are harmless vasovagal responses to stress or dehydration, some can signal serious heart problems or other conditions that need treatment. If you’re frequently fainting, talk to a doctor—especially if it happens during exercise, or if it comes with other concerning symptoms.

With the right evaluation and management, most people who deal with syncope can get their episodes under control and get back to a normal life. It might take some trial and error to figure out what works for you, but the effort is worth it for both your safety and peace of mind.

For any medical condition always consult with your physician to verify specific treatment recommendations, as individual circumstances can vary significantly. This article is for information and isn’t a substitute for medical advice from your own doctor.

Understanding Medical Care Guidelines

By John Turley

On August 7, 2024

In Commentary, Medicine

An important discussion to have with your physician.

Trivia question: What are medical guidelines? Are they rules we must follow or are they simply suggestions or are they something in between?

As we get older and have more frequent visits to the doctor, we are bound to hear one of them say, “according to the guidelines”. To understand how the guidelines apply to you, it is important to know how and why they are developed. You also need to know if there are ever times when you shouldn’t follow them.

At the end of this article, I’ll tell you about my experience with one specific guideline, and how strictly following it possibly could have led to a bad outcome for me. But first, let’s learn a little more about medical guidelines.

Medical care guidelines, also called clinical guidelines, come in two general classes. There are guidelines for preventative care and guidelines for the management of disease processes.

Guidelines have several goals. They are intended to improve public health by recommending evidence-based preventive and treatment measures to help reduce the incidence and severity of disease and improve overall public wellbeing. They’re designed to optimize resource utilization by preventing unnecessary treatment and screening tests. They are also intended to reduce health care disparities by ensuring that all recommended treatments are widely available and are based on the most up-to-date evidence so that health care across the nation is at a uniformly high level of quality.

Sources of Guidelines

Preventative care guidelines have to do with such things as cancer screening, cardiovascular health, vaccinations and immunizations, and lifestyle improvement such as diet and exercise recommendations. Disease management guidelines are developed to ensure the best possible treatment for diseases such as hypertension, diabetes and pulmonary disease.

Guidelines are developed by physician groups such as the American College of Physicians and the American Academy of Pediatrics. They are also developed by advocacy groups such as the American Cancer Society and the American Diabetes Association. Government organizations such as the Centers for Disease Control and Prevention and the National Institutes of Health also develop and promulgate medical care guidelines.

The United States Preventative Services Task Force (USPSTF) is an independent panel of experts in prevention and evidence-based medicine. They issue recommendations on a wide range of preventive services including screenings, counseling and preventative medications. The USPSTF rates medical care recommendations from Grade A, those with a high certainty of substantial benefits, all the way to Grade D, those services that are not recommended due to having no benefit or having harm that outweighs benefits. Their recommendations can be viewed at www.uspreventiveservicestaskforce.org.

Preventative care guidelines

Preventive care guidelines are designed to help identify and mitigate potential health issues before they become significant problems. They help to ensure adequate screening for significant disease processes. They are also designed to help avoid unnecessary screening which may lead to unnecessary treatment and cost.

Preventative care guidelines include such things as mammogram recommendations, colonoscopy recommendations, blood pressure and cholesterol screening, and prostate cancer screening. Preventative care guidelines also include recommendations for vaccinations both for children and adults. Recommendations on diet and the use of vitamins and supplements are one area where the guidelines seem to change frequently.

Treatment guidelines

Treatment guidelines provide a roadmap for managing specific medical conditions. These recommendations encompass diagnostic procedures, therapeutic interventions, and follow-up care to ensure optimal patient outcomes.

Treatment guidelines include recommendations for such things as initiation of blood pressure management and diabetes management. They provide recommendations for diagnostic modalities and specific medications and dosages.

For example, treatment guidelines include blood pressure levels at which medication should be started, the goal of treatment and specific medication, depending on what other medical conditions the patient may have. Similarly, there are blood glucose management recommendations for diabetics that are tailored to specific patient populations. The use of bronchodilators and pulmonary rehabilitation and oxygen therapy for lung diseases are also the subject of a series of guidelines. Treatment guidelines continually evolve as new medications are developed and our understanding of disease processes improves.

Understanding the variability in guidelines.

While the guidelines developed by the various organizations share a common goal of improving patient care, their methodologies and focus areas can differ, reflecting diverse perspectives and priorities within the medical community. There’s not a single set of guidelines that are fixed across all specialties. While the various guidelines are generally in agreement, some may have slightly different recommendations for such things as the onset and aggressiveness in treating hypertension or diabetes. There may be variations in the guidelines for diagnostic testing such as mammograms or colonoscopies. For example, the USPSTF recommends biennial mammograms for women aged 50 to 74, whereas the American College of Surgeons advises annual mammograms starting at age 45 and transitioning to biennial screening at 55. The discrepancy lies in differing interpretations of the balance between benefits and harms of more frequent screenings.

Some guidelines may also become outdated, not reflecting new medications or new treatment plans. Even where there are variations, all guidelines strive to be evidence based, patient centered, and up to date.

Additionally, guidelines need to be individualized to meet the needs of each patient. The overall guidelines are based on the most effective health care for the population as a whole. Some patients may require specialized screening or treatment. For example, women who have a family history of early onset of breast cancer or of genetic mutations may require screening at an earlier age or more frequent screening. Men with a family history of prostate cancer at a young age or of a particularly aggressive prostate cancer may require earlier screening including biopsies or may need screening beyond the age that general guidelines recommend screening is no longer necessary.

My Experience

Several years ago, I received a diagnosis no one wants to hear. Cancer! Prostate cancer to be specific. Thanks to two skilled urologists, I’ve been cancer free for five years.

But it might not have had a happy ending. Please indulge me and let me tell you my story. I think it will be worth your time.

It starts with the PSA, the prostate specific antigen. This is something every man over 40 should know about and every man over 50 should consider getting checked.

So, what is the PSA? It is a protein that is produced by both cancerous and normal cells of the prostate gland. It can be elevated by prostate cancer but it can also be elevated by prostatitis (an infection of the prostate) or an enlarged prostate (benign prostatic hypertrophy). It is checked through a simple blood test your family doctor can order as part of your annual work up.

What are the recommendations for the PSA? The USPSTF has the following three recommendations: (1) consideration of annual screening for men aged 55 to 69 with no family history of prostate cancer; this should be a shared, informed decision between the patient and his physician; (2) for men who have a significant family history of prostate cancer consideration should be given to screening beginning at age 40; (3) for men over 70 years old they recommend against screening for prostate cancer. Please note the phrase “consideration of screening”. This is not a firm recommendation.

A PSA test can have false positives that may lead to unnecessary biopsies or surgery. Only about 25% of men who have a prostate biopsy are found to have cancer. Although, it is important to recognize that a prostate biopsy does not test the entire gland. It takes samples from several areas of the prostate. It is possible, though unusual, that a cancer could be missed in the biopsy process

Additionally, most prostate cancer is very slow growing. Most men who have prostate cancer later in life will generally die of something else before they would die of prostate cancer. However, a small percentage of men will have a high-grade prostate cancer that can progress rapidly and cause their death.

I’m going to use my personal experience as a way of explaining why it is important to have a discussion with your physician about guidelines. The week before my 70th birthday I went in to get my annual physical. In our clinic we have a “birthday panel”, a set of blood tests that we draw for people annually for their physical exam. I had not planned to have my PSA checked since it was not recommended by either the USPSTF or the American Academy of Family Physicians for 70-year-olds. However, it had slipped my mind that a PSA was part of our “birthday panel”.

My PSA came back slightly elevated. Since it was a very minor elevation, I followed the guidelines and waited six months and repeated it. At that time, it increased only a small amount. The guidelines suggested repeating it again in six months. I have to admit though, I have never been a wait-and-see kind of guy. I scheduled an appointment with a urologist.

The urologist and I discussed the options. He told me that the elevation was slight, and we could wait and repeat it in 6 months or if I wished we could do a biopsy. I decided on a biopsy and then after receiving the biopsy results and having further discussions, I eventually decided on surgery. It was my decision, as it should be, made in consultation with my physician and my family.

The post-operative pathology report said that there was a high-grade carcinoma that apparently had been missed by the biopsy. It had extended beyond the capsule of the prostate. Fortunately for me it had not metastasized and had not spread to the lymph nodes, nor had it extended beyond the fat layer surrounding the prostate. Had I followed the guidelines and waited another year or even six months for a repeat biopsy, it is possible that the outcome may have been different.

What’s the bottom line?

Does my experience mean that the guidelines should be ignored? Far from it, I made an informed decision, in conjunction with my physician, on what was best for me. Additionally, I have followed the guidelines in the management of my hypertension and high cholesterol.

Healthcare guidelines are essential in promoting preventive care and effective treatment and in helping clinicians provide high-quality, evidence-based care. But the guidelines are just that, guidelines they are not “set in stone” rules for healthcare. It’s important for you to discuss your health care with your physician. Be an informed health care consumer. Ask how the guidelines are being used to manage your health care and how they may be affected by your family history or personal history. You and your physician should be involved in joint decision making. Your individual plan will generally follow the guidelines while having some variation based on what is the best care for you. And that’s what the guidelines are all about, making sure we are able to provide the best possible health care for all of our citizens.